Eyecyte-RPE™ for geographic atrophy

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 May 2024: Trial registered, NCT06394232
  2. 4 Jun 2024: Trial started, NCT06394232

The trials

NCT06394232: Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

State
Under way
Phase
Phase 1 and Phase 2
People
54 planned
Started
4 Jun 2024
Primary completion
Apr 2025
Arms
Dose Level 1-Cohort 1, Dose Level 2-Cohort 2, Dose Level 3-Cohort 3
Results
None posted
  1. 1 May 2024: Trial registered
  2. 4 Jun 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.